This article was originally published in Pharmaceutical Approvals Monthly
Peginterferon alfa-2b is approved Jan. 19 for once-weekly monotherapy to treat chronic hepatitis C in patients not previously treated with alpha interferon who have compensated liver disease and are at least 18 years old. PEG-Intron, the first pegylated interferon approved in the U.S., should be available in early February. As a Phase IV commitment, Schering will study whether PEG-Intron produces lower response rates in African-Americans. The company plans to file an application for combination use with Rebetol (ribavirin) in the first quarte
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.